ECDB-Endometrial cancer gene database

REFERENCES

Gene Name	Gene ID	Pubmed ID	Classification	Mechanism	Marker	Type	Normal Cases	Disease Cases	Age	Mean Age	Place	FIGO	Grade	Remark	Title	Journal	Volume	Year
TFF1	7031	9221798	-	-	-	-	15	64	-	-	Tenri Hospital	I (n=45); II (n=2); III (n=17)	1 (n=36); 2 (n=17); 3 (n=6)	[1] pS2 expression is likely correlated with estrogen-related endometrial carcinoma and is possibly involved in early disease progression. [2] Of the 64 samples of endometrial carcinoma; 45 (70%) expressed the pS2 protein. The average age of the patients with pS2-positive carcinomas (54.8 +/- 8.6 years) was significantly lower than that of the patients with pS2-negative carcinomas; and all premenopausal patients were positive for the pS2 protein. Among histological types; pS2 expression was observed in 33 (92%) of the 36 G1 carcinomas; but in none of the 5 nonendometrioid carcinomas. Of the 48 ER-positive carcinomas; 43 (90%) were pS2-positive and 5 were pS2-negative. Of the 40 PR-positive carcinomas; 37 (93%) were positive for pS2. There were significant associations between pS2 expression and ER/PR expression (p < 0.001).	Expression of pS2 protein in endometrial carcinomas: correlation with clinicopathologic features and sex steroid receptor status	International Journal of Cancer	74(3):237-44	1997